The findings of the ASPIRE trial have substantial implications for the future of oncology. By demonstrating the potential benefits of combining different therapeutic modalities, the trial supports the growing trend towards personalized medicine in cancer treatment. It underscores the importance of identifying biomarkers that can predict response to treatment, allowing for more tailored and effective interventions for individual patients.
